Axona (caprylidene, from Accera) has been launched as a medical food for the dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease (AD). This approval is based on data from a double-blind, randomized, placebo-controlled study of 152 patients with probable mild-to-moderate Alzheimer’s disease. Patients taking Axona demonstrated significant improvements in cognitive function by day 45 (as measured by the Alzheimer’s Disease Assessment Scale-Cognitive subscale or ADAS-Cog score). These patients also maintained a slight improvement from baseline after 90 days of daily Axona administration, whereas the placebo group demonstrated a decline.
Axona is available by prescription as a powder formulation.
For more information call (877) 649-0004 or visit www.about-axona.com.